Pruritus, a symptom commonly associated with cholestatic liver diseases [7, 9–11] and a known complication of FXR agonist therapy [17], was lower in patients treated with cilofexor vs placebo during the 12-week double-blind period of the phase 2 PSC study. Here, NR1H4 is linked to Pruritus.